Evofem Biosciences, Inc.
EVFM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $19,363 | $18,218 | $16,837 | $8,244 |
| % Growth | 6.3% | 8.2% | 104.2% | – |
| Cost of Goods Sold | $3,834 | $6,512 | $4,415 | $4,055 |
| Gross Profit | $15,529 | $11,706 | $12,422 | $4,189 |
| % Margin | 80.2% | 64.3% | 73.8% | 50.8% |
| R&D Expenses | $1,845 | $2,939 | $25,032 | $33,129 |
| G&A Expenses | $11,565 | $14,950 | $27,563 | $24,709 |
| SG&A Expenses | $20,741 | $26,614 | $71,514 | $137,861 |
| Sales & Mktg Exp. | $9,176 | $11,664 | $43,951 | $113,152 |
| Other Operating Expenses | $619 | $0 | $0 | $0 |
| Operating Expenses | $23,205 | $29,553 | $96,546 | $170,990 |
| Operating Income | -$7,676 | -$17,847 | -$84,124 | -$166,801 |
| % Margin | -39.6% | -98% | -499.6% | -2,023.3% |
| Other Income/Exp. Net | -$1,184 | $70,843 | $7,470 | -$38,374 |
| Pre-Tax Income | -$8,860 | $52,996 | -$76,654 | -$205,175 |
| Tax Expense | $0 | $17 | $44 | $17 |
| Net Income | -$8,860 | $52,979 | -$76,698 | -$205,192 |
| % Margin | -45.8% | 290.8% | -455.5% | -2,489% |
| EPS | -0.092 | 10.36 | -164.59 | -2,962.49 |
| % Growth | -100.9% | 106.3% | 94.4% | – |
| EPS Diluted | -0.092 | 0.051 | -164.59 | -2,962.49 |
| Weighted Avg Shares Out | 96,459 | 4,827 | 466 | 70 |
| Weighted Avg Shares Out Dil | 96,459 | 984,039 | 466 | 70 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16 | $31 | $85 | $15 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $756 | $1,781 | $2,046 | $1,023 |
| EBITDA | -$6,920 | -$16,066 | -$82,078 | -$165,778 |
| % Margin | -35.7% | -88.2% | -487.5% | -2,010.9% |